Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response

Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain cancer. Since median overall survival with multimodal standard therapy is only 15 months, there is a clear need for additional effective and long-lasting treatments. Dendritic cell (DC) vaccination is an exper...

Full description

Bibliographic Details
Main Authors: Dejaegher, Joost, Van Gool, Stefaan, De Vleeschouwer, Steven
Format: Online Article Text
Language:English
Published: Dove Medical Press 2014
Subjects:
Review
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Similar Items